Prof. Xin Yao 姚欣
Chief Physician, Professor
Department of Urologic Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of urinary tract tumors, including minimally invasive and robotic surgery. Comprehensive care involving chemotherapy and endocrine therapy for kidney, bladder, and prostate cancers.
Dr. Xin Yao is Chief of the Department of Urologic Oncology at Tianjin Medical University Cancer Institute & Hospital. Dr. Yao completed postdoctoral and clinical visiting scholar positions at the Van Andel Institute and Cleveland Clinic. Dr. Yao performs radical and partial nephrectomies, radical cystectomies, and transurethral resections, and pioneered laparoscopic and robotic surgery at the hospital. Dr. Yao has led five research projects and published over 20 papers.
Professional roles
- Vice Chair, Genitourinary Oncology Committee, China Anti-Cancer Association
- Executive Committee Member, American Association for Cancer Research (AACR)
- Editorial Board Member, Chinese Journal of Urology
- Member, Urology Branch, Chinese Medical Association
Name order: in Chinese the family name comes first (Yao Xin). Papers usually list the name as Xin Yao or Yao X.
Selected publications
46 papers on PubMed matched by name and affiliation; 10 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Oncol, 2026 (senior author): Reduced Nectin-4 expression in lymph node metastases of penile squamous cell carcinoma: a paired primary-metastatic analysis. PubMed 42839951
- BMC Urol, 2026 (senior author): Beyond traditional nephrometry: a 3D quantitative framework for predicting pentafecta and evaluating mediation effects in nephron-sparing surgery. PubMed 42881392
- BMC Med Imaging, 2026 (senior author): Multiphase CT-based deep learning radiomics nomogram models for preoperative WHO/ISUP grading of clear cell renal cell carcinoma: a two-center validation study. PubMed 41803747
- Urol Oncol, 2026 (senior author): Assessing pentafecta achievement and survival of retroperitoneal robotic partial nephrectomy for anterior tumors: An update on the outcomes of a long-term follow-up. PubMed 40841206
- Cancer Med, 2023 (senior author): Comparison of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma with rhabdoid and sarcomatoid differentiations. PubMed 37325945
- Front Endocrinol (Lausanne), 2023 (senior author): Use of PARP inhibitors in prostate cancer: from specific to broader application. PubMed 37152924
- Mol Carcinog, 2022 (senior author): Association of tumor mutational burden with genomic alterations in Chinese urothelial carcinoma. PubMed 34729830
- Tumour Biol, 2016 (senior author): MYSM-1 suppresses migration and invasion in renal carcinoma through inhibiting epithelial-mesenchymal transition. PubMed 26409454
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion